

A Study of Liposomal Encapsulation of Amikacin Sulfate for Increasing its Efficacy and Safety

A thesis submitted for the partial fulfillment of the requirements for the Master Degree of Pharmaceutical Sciences (Pharmaceutics)

By

Asmaa Badawy M. Darwish

Bachelor of Pharmaceutical Science, June 2007, MUST University

Research Assistant, Department of Pharmaceutical Technology,

National Research Center

Under the supervision of

Prof. Dr.

Abd Elhamed Abdallah Elshamy

Professor of Pharmaceutics and

Industrial Pharmacy,

Faculty of Pharmacy

Ain Shams University

Prof. Dr.

Mohamed Shafik El-Ridy

Professor of Pharmaceutical

Technology, Department of

Pharmaceutical Technology

National Research Center

Prof.Dr.

Gehanne A.S. Awad

Professor of Pharmaceutics and Industrial Pharmacy

Faculty of Pharmacy

Ain Shams University

2013

بسم الله الرحمن الرحيم

(و أنزل الله عليك الكتاب و الحكمة و علمك ما لم تكن تعلم و كان فضل الله
عليك عظيما)

صدق الله العظيم

سورة النساء اية ١١٣

*I DEDICATE THIS WORK TO MY BELOVED FAMILY,
MY DEAR PARENTS, MY SISTERS, MY BROTHER, MY
HUSBAND AND MY SON*

ACKNOWLEDGMENT

For **ALLAH**, the merciful, the compassionate, I kneel to express my gratitude for all the countless gifts I have been offered.

I would like to express my deepest thanks and gratitude to **Prof. Dr. Abd El-Hamid Elshamy**, Professor of Pharmaceutics and Industrial pharmacy, Department of Pharmaceutics and Industrial pharmacy, Faculty of Pharmacy, Ain Shams University, for his precious advice and guidance and for his support and encouragement throughout the work on this thesis.

I would like to express my deepest appreciation and sincere gratitude to **Prof. Dr. Mohamed Shafik El-Ridy**, Professor of Pharmaceutical Technology, Department of Pharmaceutical Technology, National Research Centre, for designing this study. His skillful guidance through various problems and full support during my studies has been an important backup for my work. I would like to deeply thank him for his close supervision, support and encouragement throughout the course of the work. He is the father and supervisor who illuminated the path to me since the beginning of my career in pharmaceutics department.

My thanks go to **Prof. Dr. Gehanne A. Awad**, Professor of Pharmaceutics and Industrial pharmacy, Department of Pharmaceutics and Industrial pharmacy, Faculty of Pharmacy, Ain Shams Universty, for her precious advice and guidance and for her support and encouragement throughout the work on this thesis.

I would like to deeply thank **Prof. Dr. Amer Ramadan**, Professor of Pharmacology, Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University and **Dr. Rehab F. Abdel-Rahman**, Researcher at Department of Pharmacology, National Research Centre, for their valuable collaboration and supervision of the *In-Vivo* biological assessment experiments.

I wish to express my appreciation to **Prof. Dr. Ahmed El-Batal**, and to the late **Prof. Dr. Adel Shehab**, professors of Pharmaceutical Microbiology, Department of Microbiology, National Centre for Radiation Research and Technology (NCRRT), Nasr city, Cairo, Egypt, for their co-operation and help in the sterility experiment.

I would like to thank all my colleagues and members of the Department of Pharmaceutical Technology, National Research Centre, for their help and co-operation during the development of this work.

I am deeply grateful for the **National Research Centre**, Dokki, Cairo, Egypt, for the generous financing of the experimental work of the thesis, through Prof. Dr. El-Ridy's projects 80/30/18 and 2/8/3.

List of Contents

Item	Page
List of Abbreviations	III
List of Tables	IV
List of Figures	V
Abstract	VI
General Introduction	1
Scope of Work	17
Chapter I: Formulation, preparation and in-vitro evaluation of amikacin sulfate liposomes.	19
Introduction	19
Experimental	26
Methodology	28
Establishment of the standard curve of amikacin sulfate & its assay using spectrophotometric method	28
Preparation of liposomes	28
Separation and washing of the liposomal suspensions	29
Effect of swelling time on the percentage of amikacin sulfate entrapped	30
<i>In-vitro</i> release profile of amikacin sulfate liposomes	31
Liposomes characterization	33
Transmission electron microscopy	33
Differential Scanning Calorimetry	34
Particle size analysis	35
Liposome zeta potential determination	35
Determination of the physical stability of liposomes	35
Sterilization of amikacin sulfate liposomes by γ -irradiation	36
Irradiation of amikacin sulfate liposomes	36
Sterility testing	36
Data analysis and statistics	38
Results & Discussion	39
Establishment of the standard curve of amikacin sulfate & its assay using spectrophotometric method	39
Entrapment efficiency of amikacin sulfate in different liposomes	40
The effect of different phospholipids surface charges and molar ratios on the percentage of amikacin sulfate entrapped	41
The effect of swelling time on the percentage of amikacin sulfate entrapped	44

<i>In-vitro</i> release profile of amikacin sulfate liposomes	46
Kinetics studies of amikacin sulfate release data	49
Characterization of amikacin sulfate liposomes	51
Transmission Electron Microscope	51
Differential Scanning Calorimetry	53
Particle Size Analysis	63
Effect of molar ratio on particle diameter of amikacin sulfate liposomes	63
Effect of surface charge on particle diameter of amikacin sulfate liposomes	63
Polydispersity Index	65
Liposome zeta potential determination	70
Determination of the physical stability of liposomes	74
Sterilization of Amikacin Sulfate liposomes	76
Sterility testing	76
Conclusions	79
Chapter II: <i>in-vivo</i> studies on selected amikacin sulfate liposomal formulations.	82
Introduction	82
Experimental	88
Methodology	89
<i>In-vivo</i> study	89
Experimental design	90
Blood and tissues cultures	91
Data analysis and statistics	91
Results and Discussion	92
Antibacterial efficacy in blood samples	92
Antibacterial efficacy in organs samples	93
Antibacterial efficacy in Spleen samples	93
Antibacterial efficacy in Liver samples	94
Antibacterial efficacy in kidney samples	96
Conclusions	102
Summary	104
References	110
Arabic summary	142

List of Abbreviations

Item	Abbreviations
Food And Drug Administration	FDA
Small Unilamellar Vesicles	SUV
Large Unilamellar Vesicles	LUV
Multilamellar Vesicles	MLV
Reticuloendothelial System	RES
Polyethylene Glycol	PEG
Central Nervous System	CNS
Multidrug Resistance	MDR
Dipalmitoyol Phosphatidyl Choline	DPPC
Neonatal Respiratory Distress System	NRDS
Acute Respiratory Distress System	ARDS
Transmission Electron Microscopy	TEM
Particle Size Distribution	PSD
Dynamic Light Scattering	DLS
Cholesterol	CHOL
Charge Inducing Agent	CIA
Dicetyl Phosphate	DCP
Stearyl Amine	SA
Entrapment Efficiency	EE
Polydispersity Index	PI
Mononuclear Phagocyte System	MPS
Colony Forming Unit	CFU

List of Tables

Table no.	Table Name	Page
1	Composition of the prepared liposomal formulations	29
2	The diffusional exponent (n) values and the corresponding deduced mechanism	33
3	Relation between concentration of amikacin sulfate and absorbance	40
4	Encapsulation efficiencies of entrapped amikacin sulfate in different liposomes	41
5	The effect of swelling time on the percentage of amikacin sulfate entrapped.	45
6	In-vitro release profiles of amikacin sulfate liposomes of different charges and molar ratios	48
7	The calculated correlation coefficients of amikacin sulfate release profile from different liposomal formulations.	50
8	Fitting of release data of amikacin sulphate from different liposomal formulations according to Korsmeyer-Peppas model	51
9	Thermodynamic parameters of Individual components of liposomes	55
10	Thermodynamic parameters of different lyophilized amikacin sulfate liposomal suspensions without and with a lyoprotectant.	60
11	Vesicle size and P.I. of the prepared liposomes	65
12	Average Zeta potential of the liposomal formulations	71
13	Physical stability of amikacin sulfate liposomes stored for 45 days at 2-8°C	75
14	Sterility testing results for F ₂ and F ₈ amikacin sulfate liposomes	78
15	Log ₁₀ CFU/ ml or gm, blood, spleen, liver and kidneys (Mean ± S.E.) For free and liposomal amikacin sulfate after 3 days against E. coli serotype (O-111) in mice (n=5)	98
16	Log ₁₀ CFU/ml or gm , blood, spleen, liver and kidney (Mean ± S.E.) for free and liposomal amikacin sulfate after 6 days against E. coli serotype (O-111) in mice (n=5)	100